Find Funding Opportunities

Notice Special Interest: Administrative Supplements Research Sexual Gender Minority SGM) Populations Admin Supp Clinical Trial Optional) Notice Number: NOT-OD-20-032 Key Dates Release Date: December 6, 2019 First Available Due Date: January 31, 2020 Expiration Date: January 26, 2021 nbsp; Related Announcements PA-18-591Administrative Supplements Existing NIH Grants Cooperative Agreements Parent Admin Supp Clinical Trial Optional) Issued National Institutes Health NIH) Sexual amp; Gender Minority Research Office SGMRO) National Center Complementary Integrative Health NCCIH) National Cancer Institute NCI) National Human Genome Research Institute NHGRI) National Heart, Lung, Blood Institute NHLBI) National Institute Aging NIA) National Institute Alcohol Abuse Alcoholism NIAAA) National Institute Allergy Infectious Diseases NIAID) National Institute Arthritis Musculoskeletal Skin Diseases NIAMS) National Institute Drug Abuse NIDA) National Institute Deafness Other Communication Disorders NIDCD) National Institute Dental Craniofacial Research NIDCR) National Institute Diabetes Digestive Kidney Diseases NIDDK) National Institute Mental Health NIMH) National Institute Minority Health Health Disparities NIMHD) National Institute Neurological Disorders Stroke NINDS) National Institute Nursing Research NINR) Additionally, following NIH Offices co-fund applications assigned these Institutes Centers: Office Behavioral Social Sciences Research OBSSR) Office Research Womens Health ORWH) Purpose mission the NIH to seek fundamental knowledge the nature behavior living systems the application that knowledge enhance health, lengthen life, reduce illness disability. NIH committed supporting research will increase scientific understanding the health wellbeing various population subpopulation groups that help establish effectiveness evidence-based health interventions services individuals within groups. NIH places high priority research populations appear have distinctive health risk profiles who also received insufficient attention investigators. this end, Notice Special Interest NOSI) announces availability administrative supplements provide funding the expansion existing research projects incorporate sexual gender minority SGM) populations, include, are limited to, those populations described NoticeNOT-OD-19-139. Basic, social, behavioral, clinical, translational, health services research relevant the missions the sponsoring NIH Institutes Centers ICs) be proposed response this solicitation. Potential applicants also encouraged review theFY 2017 Portfolio Analysisof NIH-funded SGM research identify potential research gaps may relevant this NOSI. Background Although collective knowledge base SGM health grown substantially since release the 2011 Institute Medicine the National Academy Medicine)reporton health lesbian, gay, bisexual, transgender people, continually growing body evidence indicates SGM individuals still suffer disproportionately numerous conditions, diseases, health issues compared the general population. October 2016, theNational Institute Minority Health Health Disparities, collaboration theAgency Healthcare Research Quality,announcedthat SGMs been officially designated health disparity population. designation facilitated creation tailored research projects, programs, activities, funding opportunities tackle unique health-related issues encountered SGM individuals. addition, ascertainment SGM status ongoing planned population studies been enhanced. However, SGM-specific health disparities persist today, there still urgent need novel strategies understand, measure, address, prevent them. of August 28, 2019, NIH definition sexual gender minorities" includes, is limited to, individuals identify lesbian, gay, bisexual, asexual, transgender, two-spirit, queer, and/or intersex. Individuals same-sex gender attractions behaviors those a difference sex development also included. populations also encompass those do self-identify one these terms whose sexual orientation, gender identity expression, reproductive development characterized non-binary constructs sexual orientation, gender, and/or sex. Applicants this administrative supplement propose study relevant SGM subpopulations explicitly identified this definition and/or adopt classification frameworks terminologies appropriate. Specific Areas Research Interest NOSI calls research will enrich scientific understanding how sexual orientation, gender identity, and/or being born disorders/differences sex development intersex conditions relate health outcomes, health risks, health behaviors, perceptions expectations health, access health-related services associated barriers. Appropriate topics studies these supplements include, are limited to, those listed below: Addition SGM participants an ongoing study either not originally include or not enrolled enough SGM participants make meaningful comparisons between groups; proposed studies must sufficiently powered allow meaningful comparisons Expansion an ongoing study focused one SGM group add another; proposed studies must sufficiently powered allow meaningful comparisons Expansion surveys questionnaires add items related sexual attraction, sexual behavior, sexual identity, gender identity, gender expression, and/or non-binary sex relevant appropriate Assessment reliability and/or validity measures relevant sexual attraction, sexual behavior, sexual identity, gender identity, gender expression, and/or non-binary sex Methodological strategic innovations improve recruitment retention SGM individuals any research activity Ethical, legal, social science research the implications data collection and/or research findings SGM populations Scope Support Administrative supplements be used meet increased costs are within scope the approved parent award, that unforeseen the new renewal application grant progress report non-competing continuation support submitted. Applicants this NOSI should propose research that, successful, contribute a greater understanding the health wellbeing SGM communities. Clinical trials cannot proposed be added grants do include clinical trial since would constitute change scope. IC-Specific Considerations applications submitted response this NOSI should fall within mission the IC the awarded parent grant. Applicants strongly encouraged discuss proposed supplement project the IC Program Officer the funded parent award prior submission a supplement application order ensure the proposed activity aligns the scientific priorities the IC is within scope the parent award. Scientific inquiries also addressed the contacts listed the Inquiries section below. Information Recently issued trans-NIHpolicy noticesmay affect application submission. full list policy notices published NIH provided theNIH Guide Grants Contracts. awards subject the terms conditions, cost principles, other considerations described theNIH Grants Policy Statement. Authority Regulations Awards made under authorization Sections 301 405 the Public Health Service Act amended 42 USC 241 284) under Federal Regulations 42 CFR Part 52 45 CFR Part 75. Application Submission Information Applications this initiative must submitted using following opportunity its subsequent reissued equivalent: PA-18-591- Administrative Supplements Existing NIH Grants Cooperative Agreements Parent Admin Supp Clinical Trial Optional) instructions theSF424 R&R) Application GuideandPA-18-591must followed the following additions: Application Due Dates January 31, 2020 FY 2020, January 25, 2021 FY 2021, 5:00 PM local time applicant organization. expiration date January 26, 2021. project budget periods must within currently approved project period the existing parent award. funding consideration, applicants must include ldquo;NOT-OD-20-032 without quotation marks) the Agency Routing Identifier field box 4B) the SF424 R&R form. Applications without information box 4B not considered this initiative. Requests be one year support only. project budget cannot exceed 100,000 total costs. Research Strategy section the application limited 6 pages. process Streamlined Submissions using eRA Commons cannot used this initiative. Applicants strongly encouraged notify Program Officer the IC supporting parent award a request been submitted response this NOSI order facilitate efficient processing the application. Applications do comply these instructions be delayed not accepted review. Applications nonresponsive terms this NOSI be be considered the NOSI initiative. Inquiries Please direct inquiries the Program Officer associated the parent award and/or designated contact the IC supporting parent award listed below: Scientific/Research Contact(s) Della White, PhD National Center Complementary Integrative Health NCCIH) Telephone: 301-827-6358 whitede@mail.nih.gov Liz Perruccio, PhD National Cancer Institute NCI) Telephone: 240-276-6178 Email:perruccioem@mail.nih.gov Tina Gatlin, PhD National Human Genome Research Institute NHGRI) Telephone: 301-?480-2280 Email:gatlincl@mail.nih.gov Brad Newsome, PhD National Heart, Lung, Blood Institute NHLBI) Telephone: 301-827-8170 Email:brad.newsome@nih.gov Melissa Gerald, PhD National Institute Aging NIA) Telephone: 301-?496-3136 Email:melissa.gerald@nih.gov Robert Freeman, PhD National Institute Alcohol Abuse Alcoholism NIAAA) Telephone: 301-443-8820 Email:rfreeman@mail.nih.gov Philip Renzullo, PhD, MPH National Institute Allergy Infectious Diseases NIAID) Telephone: 240-627-3041 Email:prenzullo@mail.nih.gov Heiyoung Park, PhD National Institute Arthritis Musculoskeletal Skin Diseases NIAMS) Telephone: 301-594-5032 Email:parkh1@mail.nih.gov Jeffrey Schulden, MD National Institute Drug Abuse NIDA) Telephone: 301-402-1526 Email:schuldenj@mail.nih.gov Alberto Rivera-Rentas, PhD National Institute Deafness Other Communication Disorders NIDCD) Telephone: 301-496-1804 Email:riverara@mail.nih.gov Elise Rice, PhD National Institute Dental Craniofacial Research NIDCR) Telephone: 301-594-4814 Email:elise.rice@nih.gov Tamara Bavendam, MD, MS National Institute Diabetes Digestive Kidney Diseases NIDDK) Telephone: 301-594-4733 Email:bavendamtg@mail.nih.gov Tamara Lewis Johnson, MPH, MBA National Institute Mental Health NIMH) Telephone: 301-594-7963 Email:tl247e@nih.gov Jennifer Alvidrez, PhD National Institute Minority Health Health Disparities NIMHD) Telephone: 301-594-9567 Email:alvidrezjl@mail.nih.gov Richard Benson, MD, PhD National Institute Neurological Disorders Stroke NINDS) Telephone: 301-496-9135 Email:richard.benson@nih.gov Rebecca Henry, PhD, BSN, RN National Institute Nursing Research NINR) Telephone: 301-594-5976 Email:rebecca.henry@nih.gov Rajasri Roy, PhD, MPH Office Research Womens Health ORWH) Telephone: 301-451-0993 Email:royr2@mail.nih.gov nbsp;

Notice Special Interest: Alzheimer’s-focused administrative supplements NIH grants are focused Alzheimer’s disease Notice Number: NOT-AG-20-008 Key Dates Release Date: 12/04/2019 First Available Due Date: March 06, 2020 Expiration Date: March 07, 2020 Related Announcements NOT-CA-20-019 Notice Special Interest: Alzheimers-focused Administrative Supplements NIH/NCI Grants are focused Alzheimers Disease PA-18-591 Administrative Supplements Existing NIH Grants Cooperative Agreements Parent Admin Supp Clinical Trial Optional) Issued National Institute Aging NIA) National Eye Institute NEI) National Heart, Lung, Blood Institute NHLBI) National Human Genome Research Institute NHGRI) National Institute Alcohol Abuse Alcoholism NIAAA) National Institute Allergy Infectious Diseases NIAID) National Institute Arthritis Musculoskeletal Skin Diseases NIAMS) National Institute Biomedical Imaging Bioengineering NIBIB) Eunice Kennedy Shriver National Institute Child Health Human Development NICHD) National Institute Deafness Other Communication Disorders NIDCD) National Institute Dental Craniofacial Research NIDCR) National Institute Drug Abuse NIDA) National Institute Environmental Health Sciences NIEHS) National Institute General Medical Sciences NIGMS) National Institute Mental Health NIMH) National Institute Neurological Disorders Stroke NINDS) National Institute Nursing Research NINR) National Institute Minority Health Health Disparities NIMHD) National Library Medicine NLM) Fogarty International Center FIC) National Center Complementary Integrative Health NCCIH) Division Program Coordination, Planning Strategic Initiatives, Office Research Infrastructure Programs ORIP) Purpose participating Institutes Centers ICs) inviting applications expand existing awards are currently focused Alzheimer’s disease its related dementias AD/ADRD)—frontotemporal dementia, Lewy body dementia, vascular cognitive impairment dementia, multiple etiology dementias—to allow research develop such focus. Active awards project end dates FY 2021 later eligible. award not in terminal cost extension going no cost extension FY 2020. Please note a few ICs limit cost extensions the final non-competing year an award. that reason, is important contact staff the Institute supporting award planning request. administrative supplements work proposed needs be within scope the research training is already supported. Center awards resource awards most likely be able justify supplements they tend have broad content scope. research grants also qualify the current research on related topic such cognitive decline aging; caregiving; biology neurodegeneration; genetics; imaging; computational methods; pain perception; biostatistical tools have application research AD/ADRD). NIA hosts website provides details how Alzheimer’s disease its related dementias defined provides examples currently supported research. Awardees expected seek competing support continue promising leads the research supported through supplement. Awards currently focus research Alzheimer’s disease on related dementias not eligible this program. an investigator uncertain whether project does carry Alzheimer’s focus defined NIH, the investigator contact appropriate program officer can check status. example, parent award be focusing cognitive change due chemotherapy cancer patients. Does research a current focus Alzheimer’s its related dementias? Contact program officer the award check status.) Application Submission Information Applications this initiative must submitted using following opportunity its subsequent reissued equivalent. PA-18-591 - Administrative Supplements Existing NIH Grants Cooperative Agreements Parent Admin Supp Clinical Trial Optional) instructions the SF424 R&R) Application Guide PA-18-591 must followed, the following additions: Application Due Date – March 6, 2020, 5:00 PM local time applicant organization. funding consideration, applicants must include NOT-AG-20-008” without quotation marks) the Agency Routing Identifier field box 4B) the SF424 R&R form. Applications without information box 4B not considered this initiative. Only electronic submissions be accepted this funding opportunity. one the methods described PA-18-591. Paper submissions applications submitted attachments be returned. Requests be one year support only. Individual requests be more 250,000 direct costs exclusive Facilities Administrative costs sub-contracts. Though supplement requests not limited one per award, will consider substantial additional funding an award beyond scope the funded award. process Streamlined Submissions using eRA Commons cannot used this initiative. Research Strategy section the application limited 6 pages. part the application, investigators should submit abstract the proposed research shows relevance Alzheimer’s disease and/or related dementias. Place abstract the Project Summary/Abstract section the SF424 R&R) form. work include pilot projects resource development. Institute-, Center-, Office-specific Instructions National Human Genome Research Institute: NHGRI support studies provide generalizable methods knowledge all three scientific areas genome sciences, genomic medicine, genomics society. Work proposed supplements must fall within scope the aims the NHGRI grant be supplemented Investigators encouraged contact NHGRI Scientific Program Officer the grant be supplemented before preparing application, discuss relevance the proposed research the parent grant to Institute's research priorities. Review Process IC conduct administrative reviews applications their IC separately. NIA make funds available at least ten awards each the participating ICs, provided sufficient funds available. Criteria: the work proposed within scope the active award? the work proposed focused Alzheimer’s disease its related dementias? the work likely stimulate additional activity leading progress any, all, these dementias? Inquiries Please direct inquiries to: Rene Etcheberrigaray National Institute Aging NIA) Telephone: 301-451-9798 Email: rene.etcheberrigaray@nih.gov Martha Flanders National Eye Institute NEI) Telephone: 301-451-2020 E-mail: Martha.flanders@nih.gov Jue Chen National Heart, Lung, Blood Institute NHLBI) Telephone: 301-435-0550 Email: jue.chen@nih.gov Bettie Graham National Human Genome Research Institute NHGRI) Telephone: 301-496-7531 E-mail: grahambj@exchange.nih.gov Abraham Bautista National Institute Alcohol Abuse Alcoholism NIAAA) Telephone: 301-443-9737 E-mail: Bautista@mail.nih.gov Michael Minnicozzi National Institute Allergy Infectious Diseases NIAID) Telephone: 240-627-3532 Email: minnicozzim@niaid.nih.gov Justine Buschman National Institute Arthritis Musculoskeletal Skin Diseases NIAMS) Telephone: 301-594-5032 Email: justine.muschman@nih.gov Randy King National Institute Biomedical Imaging Bioengineering NIBIB) Telephone:301-451-4780 E-mail: randy.king@nih.gov Melissa Parisi Eunice Kennedy Shriver National Institute Child Health Human Development NICHD) Telephone: 301-496-1383 Email: parisima@mail.nih.gov Judith Cooper National Institute Deafness Other Communication Disorders NIDCD) Telephone: 301-496-5061 E-mail: cooperj@nidcd.nih.gov Preethi Chander National Institute Dental Craniofacial Research NIDCR) Telephone: 301-827-4620 E-mail: Preethi.chander@nih.gov Roger Little National Institute Drug Abuse NIDA) Telephone: 301-435-1315 Email: roger.little@nih.gov Jonathan Hollander National Institute Environmental Health Sciences NIEHS) Telephone: 984-287-3269 E-mail: jonathan.hollander@nih.gov Paula Flicker National Institute General Medical Sciences NIGMS) Telephone: 301-594-0574 Email: flickerp@nigms.nih.gov Jovier Evans National Institute Mental Health NIMH) Telephone: 301-443-1369 E-mail: jevans1@mail.nih.gov Roderick Corriveau National Institute Neurological Disorders Stroke NINDS) Telephone: 301-496-5680 E-mail: roderick.corriveau@nih.gov Lois Tully National Institute Nursing Research NINR) Telephone: 301-594-5968 E-mail: lois.tully@nih.gov Priscah Mujuru National Institute Minority Health Health Disparities NIMHD) Telephone: 301-594-9765 Email: mujurup@nih.gov Hua-Chuan Sim National Library Medicine NLM) Telephone: 301-594-4882 E-mail: simh@mail.nlm.nih.gov Kathleen Michels, Ph.D. Fogarty International Center FIC) Telephone: 301-435-6031 E-mail: michelsk@ficod.fic.nih.gov Dave Clark National Center Complementary Integrative Health NCCIH) Telephone: 301-827-1916 E-mail: dave.clark@nih.gov Oleg Mirochnitchenko Office Research Infrastructure Programs ORIP) Telephone: 301-435-0748 Email: oleg.mirochnitchenko@nih.gov

This initiative will provide two years of support for planning activities necessary for initiating a Phase III clinical trial designed to validate VCID biomarkers and/or treat patients with VCID. The full spectrum of VCID is in scope, and the one or more VCID disorders(s) to be targeted in the trial must be clearly specified in the application, for example (but not limited to): vascular insults including clinical stroke, silent infarcts and microinfarcts, leukoaraiosis, cerebral amyloid angiopathy (CAA), transient ischemic attack (TIA), micro-bleeds, CADASIL, and vascular contributions to Alzheimers dementia. Planning activities may include identifying trial sites/collaborations, designing trial protocols and procedures, and addressing regulatory approvals.

The NIH Research Education Program (R25) supports research education activities in the mission areas of the NIH. The over-arching goal of this NIH Blueprint R25 program is to encourage individuals from diverse backgrounds, including those from groups underrepresented in the biomedical, behavioral, and clinical research workforce, to pursue further studies or careers in research. To accomplish the stated over-arching goal, this FOA will support creative educational activities with a primary focus on Courses for Skills Development, Research Experiences, and Mentoring Activities. The fully integrated educational activities should prepare undergraduate students from diverse backgrounds, including those from groups underrepresented in biomedical and behavioral sciences to enter Ph.D. degree programs in the neurosciences. To accomplish this goal, this initiative will provide institutional awards to develop neuroscience research education programs comprised of collaborative partnerships integrated across different educational institution types. Each partnership must include: a) one or more institutions that either: 1) have a historical and current mission to educate students from any of the populations that have been identified as underrepresented in biomedical research as defined by the National Science Foundation NSF, see http://www.nsf.gov/statistics/wmpd/) (i.e., African Americans or Blacks, Hispanic or Latino Americans, American Indians, Alaska Natives, Native Hawaiians, U.S. Pacific Islanders, and persons with disabilities) or 2) have a documented track record of recruiting, training and/or educating, and graduating underrepresented students as defined by NSF (see above), which has resulted in increasing the institution's contribution to the national pool of graduates from underrepresented backgrounds who pursue biomedical research careers; b) a research-intensive institution that has an established neuroscience or neuroscience-related program; c) integrated

The purpose of the NIH BRAIN Initiative Advanced Postdoctoral Career Transition Award to Promote Diversity (K99/R00) program is to enhance workforce diversity in the neuroscience workforce and maintain a strong cohort of new and talented, NIH-supported, independent investigators from diverse backgrounds in BRAIN Initiative research areas. This program is designed to facilitate a timely transition of outstanding postdoctoral researchers with a research and/or clinical doctorate degree from mentored, postdoctoral research positions to independent, tenure-track or equivalent faculty positions. The program will provide independent NIH research support during this transition in order to help awardees to launch competitive, independent research careers. This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing to serve as the lead investigator of an independent clinical trial, a clinical trial feasibility study, or a separate ancillary study to an existing trial, as part of their research and career development. Applicants not planning an independent clinical trial, or proposing to gain research experience in a clinical trial led by another investigator, must apply to companion FOA.

This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary study to a clinical trial. Applicants to this FOA are permitted to propose research experience in a clinical trial led by a mentor or co-mentor. Applicants proposing a clinical trial or an ancillary study to an ongoing clinical trial as lead investigator, should apply to the companion FOA.

Notice Special Interest: Advancing Research Tickborne Diseases TBDs) Notice Number: NOT-AI-20-005 Key Dates Release Date: November 12, 2019 First Available Due Date: January 05, 2020 Expiration Date: January 08, 2023 Related Announcements PA-19-055 NIH Research Project Grant Parent R01 Clinical Trial Required) PA-19-056 NIH Research Project Grant Parent R01 Clinical Trial Allowed) PA-19-270 PHS 2019-02 Omnibus Solicitation the NIH Small Business Technology Transfer Grant Applications Parent STTR R41/R42] Clinical Trial Allowed) PA-19-272 PHS 2019-02 Omnibus Solicitation the NIH, CDC, FDA Small Business Innovation Research Grant Applications Parent SBIR R43/R44] Clinical Trial Allowed) PAR-19-134 Research Enhancement Award Program REAP) Health Professional Schools Graduate Schools R15 Clinical Trial Allowed) Issued National Institute Allergy Infectious Diseases NIAID ) National Institute Arthritis Musculoskeletal Skin Diseases NIAMS) National Institute Mental Health NIMH ) National Institute Neurological Disorders Stroke NINDS) National Center Complementary Integrative Health NCCIH ) Purpose purpose this Notice to announce the National Institute Allergy Infectious Diseases NIAID), National Institute Arthritis Musculoskeletal Skin Diseases NIAMS), National Institute Mental Health NIMH), National Institute Neurological Disorders Stroke NINDS), the National Center Complementary Integrative Health NCCIH) encourage new applications advance research activities relevant the five strategic priorities identified the recently released NIH Strategic Plan Tickborne Disease Research: Improve fundamental knowledge TBDs to understand host, vector, pathogen factors drive TBD pathogenesis transmission. Elucidate host immune mechanisms response and exploited TBD pathogens. Advance research improve diagnosis TBDs using both host- pathogen-targeted approaches, including research rapid diagnostics multiplex platform approaches detect multiple tickborne pathogens. Accelerate research improve TBD prevention by supporting science design, develop, evaluate vaccines, vector control strategies, other prevention approaches. Promote research improve treatment all forms TBDs, including studies develop effective therapies treat symptoms persist after TBD treatment, therapies non-infectious TBDs, new antimicrobials. Support tools resources advance research understanding, preventing, diagnosing, treating TBDs, including repositories, genomic resources, animal models, preclinical services aid development assessment diagnostic, vaccine, therapeutic candidates. NIAID: NIAID support research the biology tickborne pathogens, vectors, animal reservoirs, human hosts, the interactions among elements they help understand underlying causes human disease. NIAID interested applications the basic science behind tickborne infections in applications seeking develop new approaches prevent, diagnose, treat those infections. NIAID also support research non-infectious TBDs, particularly alpha-gal syndrome. focus research this syndrome to understand pathogenesis develop improved diagnostics therapeutic approaches. NIAMS : NIAMS interested supporting research studies human immunity its role the initiation propagation Lyme arthritis. of systems biology approaches identify critical cellular molecular pathways involved pathogenesis encouraged. interests include studies the joint tissue remodeling pathways the cross-talk a wide range hematopoietic other cell types Lyme arthritis. Please note, NIAMS only accepts mechanistic studies meet NIH's definition a clinical trial PA-19-055. NIMH: As lead federal agency research mental disorders, NIMH interested the following areas: Basic mechanistic neuroscience studies persistent effects Lyme disease brain signaling, circuits, proximal effects functional processes such cognition are impaired mental illnesses. Research illuminate mechanisms which tick-borne diseases lead specific psychiatric complications. Research understand neurobiological basis the impact tick-borne diseases specific domains functions relevant mental health, informed the Research Domain Criteria RDoC) approach. Research decrease burden acute chronic psychiatric complications Lyme disease other tick-borne diseases. Please note, NIMH only accepts mechanistic studies meet NIH's definition a clinical trial PA-19-055. NINDS : NINDS interested supporting research the basic biology mechanisms the neurological consequences tick-borne diseases. includes developing animal cell models will facilitate studying nervous system pathogenesis these diseases developing new approaches diagnose treat neurological complications. Please note, NINDS only accepts mechanistic studies meet NIH's definition a clinical trial PA-19-055. NCCIH: NCCIH support research the mechanisms which complementary integrative health approaches improve tick-borne disease TBD) treatment and/or post-TBD symptom care. Complementary integrative approaches include mind/brain-focused practices i.e., meditation, hypnosis), body-based approaches i.e., acupuncture, massage, spinal manipulation), meditative exercise i.e., yoga, tai chi, qi gong), natural products i.e., botanicals, dietary supplements, probiotics), isolation in combination conventional medical treatments. NCCIH not accept clinical trial measures efficacy effectiveness any intervention through NOSI. NCCIH only accepts mechanistic studies meet NIH's definition a clinical trial PA-19-055. Application Submission Information notice applies due dates or after January 5, 2020 subsequent receipt dates through January 8, 2023. Submit applications this initiative using of following funding opportunity announcements FOAs) any reissues these announcement through expiration date this notice. PA-19-055 NIH Research Project Grant Parent R01 Clinical Trial Required) PA-19-056 NIH Research Project Grant Parent R01 Clinical Trial Allowed) PA-19-270 PHS 2019-02 Omnibus Solicitation the NIH Small Business Technology Transfer Grant Applications Parent STTR R41/R42] Clinical Trial Allowed) PA-19-272 PHS 2019-02 Omnibus Solicitation the NIH, CDC, FDA Small Business Innovation Research Grant Applications Parent SBIR R43/R44] Clinical Trial Allowed) PAR-19-134 Research Enhancement Award Program REAP) Health Professional Schools Graduate Schools R15 Clinical Trial Allowed) instructions the SF424 R&R) Application Guide and funding opportunity announcement used submission must followed, the following additions: funding consideration, applicants must include ldquo;NOT-AI-20-005” without quotation marks) the Agency Routing Identifier field box 4B) the SF424 R&R form. Applications without information box 4B not considered this initiative. Applications nonresponsive terms this NOSI be be considered the NOSI initiative. Inquiries Please direct inquiries to: Samuel Perdue, Ph.D. National Institute Allergy Infectious Diseases NIAID) Telephone: 240-627-3341 E-mail: sperdue@nih.gov Yisong Wang, PhD. National Center Complementary Integrative Health NCCIH) Telephone: 301-480-9483 E-mail: yisong.wang@nih.gov Su-Yau Mao, Ph.D. National Institute Arthritis Musculoskeletal Skin Diseases NIAMS) Telephone: 301-594-5032 Email: maos2@mail.nih.gov Sarah H. Lisanby, M.D.. National Institute Mental Health NIMH) Telephone: 301-451-3029 Email: lisanbysh@mail.nih.gov Wong, Ph.D. National Institute Neurological Disorders Stroke NINDS) Telephone: 301-496-1431 Email: wongm@ninds.nih.gov

The purpose of the NINDS Postdoctoral Mentored Career Development Award is to support the ability of outstanding, mentored postdoctoral researchers to develop a potentially impactful research project with a comprehensive career development plan that will enable them to launch an independent research program. Candidates are encouraged to apply for support from this NINDS K01 any time between the second through fourth year of cumulative mentored postdoctoral research experience, and may be supported by this NINDS K01 within the first 6 years of cumulative postdoctoral research experience. Because the completion of a strong, well-planned, thorough career development plan, in addition to development of an impactful research project, is a critical aspect of this K01, applications are strongly encouraged early in the postdoctoral eligibility window. By the end of the proposed K01 award period, the candidate should be poised to begin an independent research career with a well-developed, impactful research project and the expertise required to become a leader in the field. This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary study to a clinical trial. Applicants to this FOA are permitted to propose research experience in a clinical trial led by a mentor or co-mentor.

The purpose of the NINDS Postdoctoral Mentored Career Development Award is to support the ability of outstanding, mentored postdoctoral researchers to develop a potentially impactful research project with a comprehensive career development plan that will enable them to launch an independent research program. Candidates are encouraged to apply for support from this NINDS K01 any time between the second through fourth year of cumulative mentored postdoctoral research experience, and may be supported by this NINDS K01 within the first 6 years of cumulative postdoctoral research experience. Because the completion of a strong, well-planned, thorough career development plan, in addition to development of an impactful research project, is a critical aspect of this K01, applications are strongly encouraged early in the postdoctoral eligibility window. By the end of the proposed K01 award period, the candidate should be poised to begin an independent research career with a well-developed, impactful research project and the expertise required to become a leader in the field. This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing to serve as the lead investigator of an independent clinical trial, a clinical trial feasibility study, or a separate ancillary study to an existing trial, as part of their research and career development.

The purpose of this Funding Opportunity Announcement (FOA) is to further validate promising EEG and eye tracking measures that showed promising performance in the recently-completed Autism Biomarkers Consortium for Clinical Trials (ABC-CT) study. The intent of the FOA is to qualify a set of measures that can be used as biomarkers to reduce heterogeneity, and/or as sensitive and reliable objective measures of social impairment in autism spectrum disorders (ASD) clinical trials. The FOA will support a multi-site consortium to conduct a study with three primary aims to replicate and extend previous characterization of the most promising EEG and eye-tracking measures, incorporating suggestions and guidance from the FDA Biomarkers Qualification Program (BQP). A key goal of the Consortium project is to provide a community resource for broad sharing of all data generated including processed/analyzed data, with rapid and timely deposition of data into the National Database for Autism Research (NDAR). All data generated in this project are expected to be deposited in NDAR and will be accessible for use by all qualified investigators. In addition, blood (DNA) samples are expected to be deposited in the NIMH Repository and Genomics Resource for future research use. The Consortium project will assess the following: (1) whether eye-tracking, EEG paradigms, or a combination of the two, have potential utility as stratification biomarkers and/or as sensitive and reliable measures of change in ASD clinical trials; (2) the relationship (correlation) of validated clinical measures (including measures of social impairment) to eye tracking or EEG paradigms; and (3) the feasibility of collecting the same biomarker measures in a younger cohort.